Design Therapeutics

Design Therapeutics EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Design Therapeutics (DSGN) as of Oct 18, 2026 is -79.47 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -62.38 M USD — a change of 27.39% (lower).

EBITDA

-79.47 MUSD

YoY

27.39%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Design Therapeutics is 2025 -79.47 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Design Therapeutics was 2024 -62.38 M USD. It decreases by 27.39% lower compared to the previous year.

The Design Therapeutics EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
-1.91 M USD
Jan 1, 2020
-8.56 M USD
Jan 1, 2021
-35.83 M USD
Jan 1, 2022
-67.59 M USD
Jan 1, 2023
-78.19 M USD
Jan 1, 2024
-62.38 M USD
Jan 1, 2025
-79.47 M USD
The Design Therapeutics EBITDA history
YEAREBITDAYoY
-79.47 MUSD+27.39%
-62.38 MUSD-20.22%
-78.19 MUSD+15.68%
-67.59 MUSD+88.64%
-35.83 MUSD+318.78%
-8.56 MUSD+348.43%
-1.91 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Design Therapeutics Stock analysis

What does Design Therapeutics do? Design Therapeutics Inc., headquartered in Carlsbad, California, is a biotechnology company focused on developing therapies for serious degenerative disorders. The company, listed on March 26, 2021, operates in the Health Care sector with a primary emphasis on research and development of GeneTAC molecules, a novel class of small-molecule gene targeted chimera therapeutics. Its lead product candidate targets Friedreich ataxia (FA), while its second candidate addresses Fuchs Endothelial Corneal Dystrophy (FECD), both aiming to modify disease progression by targeting underlying genetic causes. The company employs 54 full-time staff. Design Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Design Therapeutics stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Design Therapeutics is -79.47 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Design Therapeutics changed from -62.38 M USD to -79.47 M USD, representing a 27.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Design Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Design Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Design Therapeutics

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Design Therapeutics